BSP:A1LN34 (USA)
Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Compare
Compare
Traded in other countries / regions
A1LN34.Brazil
•
DUL.Germany
•
ALNY.Mexico
•
0HD2.UK
•
ALNY.USA
Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.13 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 5.63 | |||||
| Debt-to-EBITDA | -1.35 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.71 | |||||
| Beneish M-Score | -3.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 112.3 | |||||
| 3-Year EBITDA Growth Rate | 11 | |||||
| 3-Year EPS without NRI Growth Rate | 1.7 | |||||
| 3-Year FCF Growth Rate | 4 | |||||
| 3-Year Book Growth Rate | -27.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 47.12 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.88 | |||||
| 9-Day RSI | 82.16 | |||||
| 14-Day RSI | 80.64 | |||||
| 6-1 Month Momentum % | 2.04 | |||||
| 12-1 Month Momentum % | -22.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.76 | |||||
| Quick Ratio | 3.62 | |||||
| Cash Ratio | 3.21 | |||||
| Days Inventory | 216.92 | |||||
| Days Sales Outstanding | 64.81 | |||||
| Days Payable | 136.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.4 | |||||
| Operating Margin % | -80.82 | |||||
| Net Margin % | -110.91 | |||||
| ROE % | -176.73 | |||||
| ROA % | -28.2 | |||||
| ROIC % | -65.94 | |||||
| ROC (Joel Greenblatt) % | -112.51 | |||||
| ROCE % | -28.62 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.53 | |||||
| PB Ratio | 154.36 | |||||
| Price-to-Tangible-Book | 153.52 | |||||
| EV-to-EBIT | -31.46 | |||||
| EV-to-Forward-EBIT | -38.26 | |||||
| EV-to-EBITDA | -35.11 | |||||
| EV-to-Forward-EBITDA | -44.32 | |||||
| EV-to-Revenue | 29.05 | |||||
| EV-to-Forward-Revenue | 23.97 | |||||
| EV-to-FCF | -38.92 | |||||
| Price-to-Median-PS-Value | 0.35 | |||||
| Earnings Yield (Greenblatt) % | -3.18 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 4,648.58 | ||
| EPS (TTM) (R$) | -2.141 | ||
| Beta | 0 | ||
| Volatility % | 52.56 | ||
| 14-Day RSI | 80.64 | ||
| 14-Day ATR (R$) | 1.788794 | ||
| 20-Day SMA (R$) | 43.015 | ||
| 12-1 Month Momentum % | -22.74 | ||
| 52-Week Range (R$) | 29.85 - 58.8 | ||
| Shares Outstanding (Mil) | 2,400.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||